BBIO - Alnylam downgraded at Oppenheimer ahead of key data readout
2023-10-11 12:26:19 ET
More on Alnylam
- Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One
- Alnylam: Why The FDA Rejection Of Onpattro Is A Minor Setback
- Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility
- Alnylam sends Arbutus lower after FDA snub for amyloidosis drug
- Alnylam U.S. label expansion for amyloidosis drug denied
For further details see:
Alnylam downgraded at Oppenheimer ahead of key data readout